Medications for Actively Bleeding Peptic Ulcer Disease
For actively bleeding peptic ulcer disease, immediately initiate high-dose intravenous proton pump inhibitor (PPI) therapy with an 80 mg bolus followed by continuous infusion at 8 mg/hour for 72 hours after endoscopic hemostasis. This regimen substantially reduces rebleeding risk and is the cornerstone of pharmacologic management 1, 2, 3.
Immediate Pharmacologic Management
Proton Pump Inhibitor Therapy
High-dose IV PPI protocol:
- Loading dose: 80 mg IV bolus (omeprazole or equivalent)
- Maintenance: 8 mg/hour continuous IV infusion for 72 hours
- Transition: After 72 hours, switch to oral PPI 40 mg twice daily for 14 days, then once daily 4, 1, 2
The evidence strongly supports this approach. A landmark randomized trial demonstrated that high-dose omeprazole infusion reduced rebleeding from 22.5% to 6.7% compared to placebo, with most benefit occurring during the first 3 days 3. The 2020 WSES guidelines and 2019 International Consensus Group both provide strong recommendations for this regimen following endoscopic therapy 4, 2.
Important caveat: Pre-endoscopic PPI therapy receives only a conditional recommendation (Grade C) 5. While it may downgrade endoscopic stigmata, it should not delay urgent endoscopy. However, given the excellent safety profile, empirical high-dose PPI can be considered while awaiting endoscopy 5.
Alternative Dosing Considerations
If continuous infusion is unavailable, intermittent high-dose IV PPI (40 mg every 6 hours) is an acceptable alternative, though slightly less effective than every-6-hour dosing compared to every-12-hour dosing 6. Do not use H2-receptor antagonists—they do not reliably maintain gastric pH above 6, which is necessary for clot stability 1.
Subsequent H. pylori Management
Testing Protocol
All patients with bleeding peptic ulcers must be tested for H. pylori 4, 5. This is a Grade A recommendation with strong evidence showing that eradication reduces rebleeding from 26% to 0-2% 4, 5.
Critical pitfall: Acute bleeding increases false-negative rates for H. pylori testing 5. If initial testing is negative, repeat testing after the acute episode 2.
Eradication Therapy
Start H. pylori eradication after 72-96 hours of IV PPI therapy 4. The regimen depends on local clarithromycin resistance patterns:
First-line (low clarithromycin resistance):
- PPI standard dose twice daily
- Clarithromycin 500 mg twice daily
- Amoxicillin 1000 mg twice daily (or Metronidazole 500 mg twice daily if penicillin-allergic)
- Duration: 14 days 4
Sequential therapy (high clarithromycin resistance):
- Days 1-5: PPI twice daily + Amoxicillin 1000 mg twice daily
- Days 6-10: PPI twice daily + Clarithromycin 500 mg twice daily + Metronidazole 500 mg twice daily 4
Second-line (if first-line fails):
- PPI standard dose twice daily
- Levofloxacin 500 mg once daily (or 250 mg twice daily)
- Amoxicillin 1000 mg twice daily
- Duration: 10 days 4
Medications NOT Recommended
Somatostatin/Octreotide: Despite theoretical benefits (acid suppression, reduced splanchnic blood flow), meta-analyses show insufficient evidence for routine use 1.
Tranexamic acid: While it may reduce surgical intervention, it does not reduce rebleeding and has mixed mortality data. Not recommended routinely 1.
H2-receptor antagonists: Ineffective—do not reliably maintain gastric pH >6 required for platelet aggregation and clot stability 1.
Long-term Prevention
For patients requiring continued NSAIDs or antiplatelet therapy after ulcer healing:
- Continue PPI therapy indefinitely 7, 2
- For very high-risk patients (prior ulcer bleeding), even COX-2 inhibitors plus PPI carry ~10% annual rebleeding risk 8
- If low-dose aspirin is for secondary cardiovascular prevention, restart as soon as cardiovascular risk outweighs bleeding risk 2, 9
The evidence hierarchy is clear: High-dose IV PPI after endoscopic hemostasis is the only pharmacologic intervention with Grade A evidence for reducing morbidity and mortality in actively bleeding peptic ulcers 1, 2, 3.